American International Group, Inc. Chinook Therapeutics, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$18.66 - $38.58 $64,488 - $133,332	3,456 Added 14.13%	27,923 $1.07 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $10,485 - $13,051	487 Added 2.03%	24,467 $566,000
Q4 2022 Feb 10, 2023	BUY	$18.63 - $27.35 $5,700 - $8,369	306 Added 1.29%	23,980 $628,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $56,539 - $75,461	3,229 Added 15.79%	23,674 $465,000
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $5,237 - $7,820	416 Added 2.08%	20,445 $358,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.69 $8,858 - $12,300	-737 Reduced 3.55%	20,029 $328,000
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $28,275 - $44,515	2,645 Added 14.6%	20,766 $339,000
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $5,738 - $7,415	499 Added 2.83%	18,121 $231,000
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $134,422 - $187,598	9,884 Added 127.73%	17,622 $249,000
Q1 2021 May 07, 2021	BUY	$14.17 - $19.11 $297 - $401	21 Added 0.27%	7,738 $120,000
Q4 2020 Feb 12, 2021	BUY	$11.9 - $20.91 $91,832 - $161,362	7,717 New	7,717 $122,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.